New combo therapy aims to tame rare liver disease in Long-Term trial
NCT ID NCT06755541
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the long-term safety of combining fenofibrate with standard treatment (ursodeoxycholic acid) in 150 adults with primary biliary cholangitis, a chronic liver disease. Participants previously completed a related study and will take fenofibrate capsules daily. Researchers will monitor side effects, deaths, liver transplants, and liver enzyme levels to see if the combination is safe and tolerable over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fenofibrate and ursodeoxycholic acid
- What this could lead to
- If it works, this could provide a safe long-term treatment option to help control PBC and reduce the need for liver transplants.
- What could go wrong
- This is an open-label study with no placebo group, so results may be less reliable. Side effects from fenofibrate are possible, and it may not improve outcomes for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xijing hospital
RECRUITINGXi'an, Shaanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common cholesterol drug help manage a rare liver disease?
- One pill may tame both itchy skin and stubborn liver disease
- Can a smartwatch help manage a rare liver disease? stanford study investigates
- Can breathing and meditation ease PBC symptoms? new study says maybe.
- New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
- 3000-Patient study aims to predict PBC outcomes from blood tests